Repligen Co. (NASDAQ:RGEN) Shares Sold by Van ECK Associates Corp

Van ECK Associates Corp trimmed its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 14.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 46,536 shares of the biotechnology company's stock after selling 8,016 shares during the period. Van ECK Associates Corp owned approximately 0.08% of Repligen worth $8,367,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Signaturefd LLC lifted its stake in Repligen by 44.1% in the 3rd quarter. Signaturefd LLC now owns 281 shares of the biotechnology company's stock worth $45,000 after purchasing an additional 86 shares in the last quarter. Milestone Investment Advisors LLC bought a new stake in Repligen during the third quarter valued at $61,000. Headlands Technologies LLC purchased a new stake in shares of Repligen in the 3rd quarter valued at about $75,000. Nisa Investment Advisors LLC boosted its position in shares of Repligen by 67.6% during the 3rd quarter. Nisa Investment Advisors LLC now owns 533 shares of the biotechnology company's stock valued at $85,000 after acquiring an additional 215 shares during the last quarter. Finally, Annis Gardner Whiting Capital Advisors LLC purchased a new position in shares of Repligen during the third quarter worth about $95,000. Institutional investors own 97.64% of the company's stock.

Insider Activity at Repligen

In related news, VP Ralf Kuriyel sold 3,517 shares of the stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $193.73, for a total value of $681,348.41. Following the completion of the transaction, the vice president now directly owns 24,260 shares of the company's stock, valued at $4,699,889.80. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other news, CEO Anthony Hunt sold 16,707 shares of the firm's stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $197.44, for a total value of $3,298,630.08. Following the completion of the transaction, the chief executive officer now owns 185,249 shares in the company, valued at approximately $36,575,562.56. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Ralf Kuriyel sold 3,517 shares of the company's stock in a transaction on Monday, March 11th. The stock was sold at an average price of $193.73, for a total value of $681,348.41. Following the completion of the sale, the vice president now directly owns 24,260 shares in the company, valued at $4,699,889.80. The disclosure for this sale can be found here. Insiders have sold a total of 25,597 shares of company stock worth $5,039,532 over the last quarter. Corporate insiders own 1.20% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on RGEN. JPMorgan Chase & Co. lowered their target price on shares of Repligen from $230.00 to $200.00 and set an "overweight" rating on the stock in a research note on Thursday. KeyCorp upped their target price on Repligen from $210.00 to $220.00 and gave the stock an "overweight" rating in a research note on Thursday, February 15th. Finally, Stifel Nicolaus lifted their price target on shares of Repligen from $165.00 to $207.00 and gave the stock a "buy" rating in a research note on Thursday, February 22nd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $197.75.

Repligen Trading Up 0.4 %

Shares of Repligen stock traded up $0.74 on Friday, hitting $167.05. The stock had a trading volume of 454,984 shares, compared to its average volume of 538,521. The stock's 50-day simple moving average is $180.81 and its two-hundred day simple moving average is $174.09. Repligen Co. has a one year low of $110.45 and a one year high of $211.13. The company has a quick ratio of 5.75, a current ratio of 6.35 and a debt-to-equity ratio of 0.26. The stock has a market cap of $9.33 billion, a price-to-earnings ratio of 668.23, a PEG ratio of 5.44 and a beta of 1.03.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.29 by ($0.01). The firm had revenue of $151.31 million during the quarter, compared to analysts' expectations of $150.06 million. Repligen had a net margin of 2.44% and a return on equity of 3.95%. Repligen's revenue was down 17.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.64 EPS. As a group, sell-side analysts predict that Repligen Co. will post 1.46 EPS for the current year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.